Neutropenia screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There are no routine screening recommendations for [[neutropenia]]. [[Neutropenia]] is typically identified incidentally on routine blood work or while monitoring after cytotoxic therapy. | There are no routine screening recommendations for [[neutropenia]]. [[Neutropenia]] is typically identified incidentally on routine blood work or while monitoring after cytotoxic therapy.<ref name="PMID21258094">{{cite journal |author=Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. |title=Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america|journal=Clin Infect Dis. |volume=52 |issue=4 |pages=e56-95 |year=2011 |pmid=21258094 |doi=|url=http://www.ncbi.nlm.nih.gov/pubmed/21258094}}</ref> | ||
==References== | ==References== | ||
Revision as of 05:40, 7 November 2016
|
Neutropenia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neutropenia screening On the Web |
|
American Roentgen Ray Society Images of Neutropenia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Daniel A. Gerber, M.D. [2]
Overview
There are no routine screening recommendations for neutropenia. Neutropenia is typically identified incidentally on routine blood work or while monitoring after cytotoxic therapy.[1]
References
- ↑ Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. (2011). "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america". Clin Infect Dis. 52 (4): e56–95. PMID 21258094.